Table 1.
Characteristics of patients with breast cancer who received neoadjuvant chemotherapy followed by total mastectomy stratified into PMRT and No-PMRT groups.
| Variable | TM |
|||
|---|---|---|---|---|
| PMRT (N = 2917) | No-PMRT (N = 1319) | p | ||
| Age | Mean (SD) | 51.3 (10.3) | 52.0 (10.9) | 0.1108 |
| Median (IQR: Q1, Q3) | 51 (44,58) | 51 (44,59) | ||
| 20–49 | 1301 (69.8%) | 562 (30.2%) | 0.2263 | |
| 50+ | 1616 (68.1%) | 757 (31.9%) | ||
| Diagnosis year | 2007–2010 | 956 (63.2%) | 556 (36.8%) | <0.0001 |
| 2011–2015 | 1961 (72.0%) | 763 (28.0%) | ||
| CCI scores | 0 | 2423 (69.9%) | 1042 (30.1%) | 0.0065 |
| 1 | 350 (64.1%) | 196 (35.9%) | ||
| 2+ | 144 (64.0%) | 81 (36.0%) | ||
| Differentiation | Well | 185 (6.3%) | 86 (6.5%) | 0.9504 |
| Moderate | 1505 (51.6%) | 690 (52.3%) | ||
| Poor | 1227 (42.1%) | 543 (41.2%) | ||
| AJCC clinical stages | I | 66 (57.9%) | 48 (42.1%) | <0.0001 |
| II | 995 (77.7%) | 285 (22.3%) | ||
| III | 959 (58.2%) | 690 (41.8%) | ||
| IV | 897 (75.2%) | 296 (24.8%) | ||
| ypT | ypT0 | 197 (60.2%) | 130 (39.8%) | <0.0001 |
| ypT1 | 749 (64.1%) | 419 (35.9%) | ||
| ypT2 | 1163 (68.6%) | 532 (31.4%) | ||
| ypT3–4 | 808 (77.2%) | 238 (22.8%) | ||
| ypN | ypN0 | 822 (71.6%) | 326 (28.4%) | <0.0001 |
| ypN1 | 1291 (84.6%) | 235 (15.4%) | ||
| ypN2–3 | 66 (57.9%) | 48 (42.1%) | <0.0001 | |
| yp pathologic AJCC stage | pCR | 154 (56.0%) | 121 (44.0%) | <0.0001 |
| IA | 277 (50.5%) | 272 (49.5%) | ||
| IB | 36 (65.5%) | 19 (34.5%) | ||
| IIA | 448 (53.6%) | 388 (46.4%) | ||
| IIB | 456 (71.3%) | 184 (28.8%) | ||
| IIIA–IIIC | 1546 (82.2%) | 335 (17.8%) | ||
| NACT regimen | Taxanes | 1176 (78.0%) | 331 (22.0%) | <0.0001 |
| Anthracycline | 772 (59.2%) | 533 (40.8%) | ||
| Both | 833 (73.1%) | 306 (26.9%) | ||
| Neither | 136 (47.7%) | 149 (52.3%) | ||
| Nodal surgery | ALND | 2104 (70.3%) | 890 (29.7%) | <0.0001 |
| SLNB | 813 (65.5%) | 429 (34.5%) | ||
| ER/PR | Negative | 1401 (68.2%) | 653 (31.8%) | 0.3726 |
| Positive | 1516 (69.5%) | 666 (30.5%) | ||
| HER2 | Negative | 1876 (67.2%) | 915 (32.8%) | 0.0013 |
| Positive | 1041 (72.0%) | 404 (28.0%) | ||
| Hospital level | Academic/research facility | 1595 (62.8%) | 946 (37.2%) | <0.0001 |
| Others | 1322 (78.0%) | 373 (22.0%) | ||
PMRT, postmastectomy radiation therapy; T, tumor; N, nodal; NACT, neoadjuvant chemotherapy; TM, total mastectomy; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete response; ALND, axillary lymph node dissection; SLNB, sentinel lymph node biopsy; SD, standard deviation; CCI, Charlson comorbidity index; AJCC, American Joint Committee on Cancer; ypT, postchemotherapy pathologic tumor stages; ypN, postchemotherapy pathologic nodal stages; IQR, interquartile range.